论文部分内容阅读
目的:研究缺氧诱导因子-1α(HIF-1α)在人垂体腺瘤中的表达,对HIF-1α蛋白表达与肿瘤分级进行相关性分析,探讨其表达水平与垂体腺瘤侵袭性的关系。方法:集影像学检查、内分泌学检查及病理诊断的垂体腺瘤60例,分为侵袭组和非侵袭组,其中侵袭组36例,非侵袭组24例;对照组正常脑组织5例。免疫组织化学技术检测HIF-1α蛋白的表达,结合临床资料进行统计学分析。分析垂体腺瘤HIF-1α蛋白的表达水平并与对照组进行比较,比较侵袭组和非侵袭组垂体腺瘤之间HIF-1α蛋白表达水平的差异。结果:HIF-1α蛋白在垂体腺瘤中的表达明显高于对照组,二者比较,x20.05,1=12.392,P<0.001,有显著性差异;侵袭组HIF-1α蛋白的表达较非侵袭组显著增高,二者比较,x20.05,1=24.658,P<0.001,有显著性差异。结论:HIF-1α是垂体腺瘤侵袭过程中的重要调控因子,与垂体腺瘤的大小、分级以及侵袭性密切相关,其作用机制有待进一步研究,其表达程度可用作垂体腺瘤预后的评估指标,为垂体腺瘤术后的复发以及相应的辅助治疗提供判断依据。有可能为人们靶向肿瘤缺氧来开发新药物提供新的作用靶点。
OBJECTIVE: To study the expression of hypoxia inducible factor-1α (HIF-1α) in human pituitary adenoma and to analyze the relationship between HIF-1α protein expression and tumor grade, and to explore the relationship between the expression of HIF-1α and invasiveness of pituitary adenoma. Methods: Sixty cases of pituitary adenomas were divided into invasive group and noninvasive group, including 36 cases of invasive group and 24 cases of non-invasive group, and 5 cases of normal brain tissue in control group. Immunohistochemistry was used to detect the expression of HIF-1αprotein, and the clinical data were used for statistical analysis. The expression of HIF-1αprotein in pituitary adenomas was analyzed and compared with the control group. The differences of HIF-1αprotein expression levels between invasive group and non-invasive pituitary adenomas were compared. Results: The expression of HIF-1αprotein in pituitary adenomas was significantly higher than that in the control group. There was significant difference between the two groups (x20.05,1 = 12.392, P <0.001). The expression of HIF- Invasive group was significantly higher, the two compared, x20.05,1 = 24.658, P <0.001, significant difference. Conclusion: HIF-1α is an important regulator of pituitary adenomas invasion and closely related to the size, grading and invasiveness of pituitary adenomas. Its mechanism of action needs further study, and its expression level can be used as an assessment of the prognosis of pituitary adenomas Indicators for postoperative recurrence of pituitary adenomas and the corresponding adjuvant therapy provide the basis for judgment. It may provide a new target for targeting cancer hypoxia to develop new drugs.